222 results about "Membrane protein" patented technology

The present invention relates to the field of lentiviral delivery. Specifically provided are a mutated vesicular virus envelope protein and the use thereof in lentiviral vector packaging.

The invention discloses an all-optical three-dimensional scanning confocal fluorescent microscopic imaging device and an implementation method thereof. According to the invention, through a deep learning driven adaptive regulation and control method, CNN is adopted to process spatial distribution data and dynamically regulate and control a phase hologram and the light intensity and phase compensation of a laser, so that the focal point of exciting light is subjected to aberration-free axial displacement, a bidirectional parallel optical scanning track of a two-dimensional scanning system is optimized, and all-optical three-dimensional scanning is realized; lSTM and TCN are combined to obtain a time sequence dependency relationship, a laser light source, an adjustable diaphragm, an electric focus-adjustable lens and a photoelectric detector are integrally controlled, efficient synchronization and automatic operation and high-speed axial focusing adjustment are realized, errors and time sequence mismatch are eliminated, optical characteristics of different samples and environmental interference are automatically adapted, and high-quality imaging is kept. The robustness and the applicable scene range of the system are improved; the method is used for model biological embryo real-time tracking, intracellular signal molecule dynamic visualization, cell membrane protein migration and aggregation observation and intracellular organelle interaction tracking.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The invention discloses a preparation method of a monomeric protein and hydrophobic transmembrane protein complex, which comprises the following steps: 1) preparing a protein A containing the monomeric protein, the C end of the monomeric protein in the protein A having a connection sequence for connecting with the hydrophobic transmembrane protein; the connecting sequence comprises at least two amino acids; preparing a protein B containing a hydrophobic transmembrane protein monomer; and 2) connecting the protein A with the protein B, and polymerizing the hydrophobic transmembrane protein monomers in the plurality of protein B to form the hydrophobic transmembrane protein, thereby obtaining the monomeric protein and hydrophobic transmembrane protein complex.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

Fusion proteins containing a targeting sequence, an exosporium protein, or an exosporium protein fragment that targets the fusion protein to the exosporium of a Bacillus cereus family member are provided. Recombinant Bacillus cereus family members expressing such fusion proteins are also provided. Genetically inactivated Bacillus cereus family members and recombinant Bacillus cereus family members that overexpress exosporium proteins are also provided. Seeds coated with the recombinant Bacillus cereus family members and methods for using the recombinant Bacillus cereus family members (e.g., for stimulating plant growth) are also provided. Various modifiations of the recombinant Bacillus cereus family members that express the fusion proteins are further provided. Fusion proteins comprising a spore coat protein and a protein or peptide of interest, recombinant bacteria that express such fusion proteins, seeds coated with such recombinant bacteria, and methods for using such recombinant bacteria (e.g., for stimulating plant growth) are also provided.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

This disclosure relates to a recombinant adenovirus comprising a polynucleotide encoding DENV envelope protein and a polynucleotide encoding ferritin heavy chain protein, and uses thereof. This disclosure also provides a recombinant adenovirus comprising a polynucleotide encoding DENV (Dengue Virus) envelope protein and a polynucleotide encoding ferritin heavy chain protein, and a vaccine composition for preventing DENV infection comprising the recombinant adenovirus as an effective ingredient.

To provide agents for promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production by finding substances having excellent activity in promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production.SOLUTION: An epidermal keratinocyte growth promoting agent of the invention comprises one or more effective ingredients selected from the group consisting of 2-ketoglutaric acid, 2-isopropyl malate, inosine 5'-monophosphoric acid, succinic acid, malic acid and pyruvic acid. Also, a filaggrin mRNA expression promotor, a serine palmitoyltransferase mRNA expression promotor, an involucrin expression promotor of the invention comprise, as an effective ingredient, 2-ketoglutaric acid. Further an ATP production promotor of the invention comprises 2-isopropyl malate as an effective ingredient.SELECTED DRAWING: None

The application relates to a hybridoma cell strain 1B6A2 secreting an anti-fish T lymphocyte surface membrane protein CD28 monoclonal antibody, the hybridoma cell strain 1B6A2 is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202291, and the preservation date is May 5, 2022. The application provides a powerful tool for simulating a second signal in vitro and exploring a CD28-mediated T cell adaptive immune response mechanism.

To provide methods for treating viral infections including SARS-CoV-2, and to provide polymers for use in such treatments.SOLUTION: Provided are improved amphiphilic comb-type polymers with well-controlled molecular weights, structures, and end groups, and hydrophilic backbones with regularly arranged hydrophobic substituents. The polymers self-assemble in an aqueous environment to form core-corona nanoparticles that are capable of disrupting envelope proteins of a virus and can further encapsulate antiviral drugs or their prodrugs. Regularly arranged targeting groups can also mediate the attachment of the nanoparticles to an envelope of the virus.SELECTED DRAWING: Figure 2

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention discloses a lysosome targeted degradation system based on a DNA phase separation aggregate as well as a preparation method and application of the lysosome targeted degradation system, and belongs to the technical field of biological medicine and nanotechnology. The lysosome targeted degradation system based on the DNA phase separation aggregate comprises an RNA-DNA tetrahedral framework with a cohesive end, the RNA-DNA tetrahedral framework is formed by self-assembly of a core chain and an edge chain through complementary base pairing, the edge chain is a DNA-RNA chimeric oligonucleotide chain, and the DNA-RNA chimeric oligonucleotide chain is a DNA-RNA chimeric oligonucleotide chain. One or more sections of RNA ribonucleotide sequences which can be specifically recognized and cut by RNase H enzyme are embedded in the sequence, and the tail end of the RNA ribonucleotide sequence is modified with a cohesive tail end for driving phase separation and a cell membrane anchoring group; the RNA-DNA tetrahedral framework is modified with an aptamer of a targeted membrane protein. After entering cells, the system is subjected to liquid-liquid phase separation in a lysosome acid environment through interaction of cohesive ends, a micron-sized large-size aggregate is formed in situ, the residence time of a nano-drug in the lysosome is prolonged, and efficient degradation of target membrane protein is realized.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

Provided herein are compositions comprising a muscle (cardiac and / or skeletal) cell targeting peptide linked to or inserted into a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn-RGD-n-mer-Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors with engineered capsid or envelope proteins are provided, along with uses thereof.

Antibodies and other molecules including an antigen binding region of an antibody that immunospecifically binds to a surface unit or a transmembrane unit of a Human endogenous retrovirus-K (HERV-K) Env protein are provided. The antibodies and other molecules typically include six complementarity determining regions (CDRs). In preferred forms the antibodies and other molecules immunospecifically bind to the amino acid sequence SEQ ID NO:223 and / or 224. Chimeric antigen receptors (CAR) formed using the provided antibodies are also provided, as are cell expressing the CAR. Methods of detecting HERV-K Env, and use thereof of various other methods such as diagnostic methods are also provided. Method of treatment for HERV-K Env protein-related diseases and disorders are also provided.

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

A vaccine for use in the prophylaxis and / or treatment of a diseaseThe present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.

The invention relates to the technical field of organelle separation, and provides a method for rapid purification of peroxisome and oxidation regulation analysis of ultra-long chain fatty acid. The method comprises the following steps: introducing a nucleic acid sequence for coding a fusion protein into a target cell to obtain a cell material, the fusion protein comprising a truncated sequence derived from a peroxisome membrane protein and a tag sequence for affinity purification; taking the cell material as a sample, and separating the peroxisome with the fusion protein from the cell by utilizing an affinity ligand on the basis of a high affinity binding principle. Therefore, according to the method disclosed by the invention, the peroxisome can be rapidly and efficiently enriched, and the whole purification process can be completed within 30 minutes, so that the experimental period is greatly shortened; core protein components of target organelles can be efficiently reserved, and the metabolic activity of peroxisome can be maintained through a complete membrane structure and an internal environment; meanwhile, the same purified sample can synchronously support proteome and metabolome analysis, and direct association of'protein-metabolism 'data is realized.

To provide methods of identifying new substrates for proteases and methods of using these substrates in a variety of therapeutic, diagnostic and prophylactic indications.SOLUTION: The invention relates generally to: polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA); activatable antibodies and other large molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator; and methods of making these polypeptides that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and methods of use in a variety of therapeutic, diagnostic and prophylactic indications.SELECTED DRAWING: Figure 4A

The invention discloses application of PD-L1 as a drug target for resisting pseudorabies virus infection, the invention discloses PD-L1 as a key host limiting factor for pseudorabies virus infection for the first time, and knockout of PD-L1 can significantly promote replication of pseudorabies virus and induce apoptosis and inflammatory response of host cells. And PD-L1 overexpression can effectively inhibit proliferation of the pseudorabies virus and induce apoptosis and inflammatory response of host cells. Mechanism research results show that PD-L1 can be combined with envelope proteins gB and gD of the pseudorabies virus, and the effect of resisting pseudorabies virus infection is achieved through a cGAS-STNG-IFN pathway. The further research finds that the 125th arginine (ARG125) and the 271th lysine (LYS271) of the PD-L1 protein play a key role in the anti-pseudorabies virus infection effect of the PD-L1. The invention provides a new target spot for drugs for preventing or treating pseudorabies virus infection, and has a good application prospect in the aspect of resisting pseudorabies virus.

The present application relates to the field of biotechnology, in particular to a kit based on functionalized magnetic beads and application thereof in the field of stem cells. The functionalized magnetic beads of the present application are loaded with extracellular matrix proteins on the surface, and the extracellular matrix proteins are selected from collagen. The functionalized magnetic beads of the present application realize efficient capture and enrichment of collagen-bound transmembrane proteins, combined with mass spectrometry identification, and are suitable for screening stem cell transmembrane proteins, studying the action sites of stem cells and matrix, or developing drugs targeting stem cells. The kit and method of the present application have the technical advantages of simple operation, good stability and strong specificity, and provide a powerful tool for systematic study of the cell-matrix interaction mechanism mediated by stem cell transmembrane proteins.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

Methods and compositions for treating a corneal wound and / or increasing a population of limbal epithelial stem cells (LESCs) and / or early transit amplifying cells (eTAs) in the limbal epithelium of a subject in need thereof. The methods can include administering a therapeutic agent to the subject that: i) results in an increase in concentration of IFITM1 (Interferon Induced transmembrane Protein 1) in the limbal epithelium of the subject; and / or ii) results in a decrease in concentration of OVOL1 (Ovo Like Zinc Finger 1) in the limbal epithelium of the subject. Also provided are adeno-associated viruses (AAVs). The AAVs comprise a heterologous nucleic acid sequence encoding IFITM1 or a variant thereof, operably linked to a regulatory sequence.

The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).

Disclosed herein, in aspects, are compositions, methods, kits, and systems relating to delivery of payload into cells, for instance, for in vivo delivery via lipid delivery particles that comprise a chimeric envelope protein.

The disclosure provides the structure of an MFSD2A-SYNC2 complex together with functional data that revealed important molecular aspects of MFSD2A transport cycle, receptor-mediated cell-cell fusion, and pharmacology and resulted in the identification of two novel allosteric modulators of MFSD2A, which are two soluble fragments of SYNC2, namely SYNC2su-co and SYNC2su-co-2, representing first-in-class molecules to inhibit MFSD2A LPCs uptake and increase transcytosis rate.

The application discloses a kind of bionic transmembrane protein affinity chromatography column and its preparation method and application.The system (iSTAC) realizes the in-situ construction of transmembrane protein in highly bionic dynamic microenvironment by integrating cell-free protein synthesis, functional mesoporous silica modification and amphiphilic (AH) peptide stabilized planar lipid bilayer technology.The core is to use long-chain PEG-24 crosslinking agent to retain lipid bilayer on the surface of silica gel, provide sufficient conformational dynamic space for multi-transmembrane protein, and introduce AH peptide to repair membrane defects, ensure that the receptor realizes directional embedding while maintaining natural functional attributes.The preparation cycle is shortened from 168 hours to 5 hours, which significantly improves the efficiency of targeted drug screening and in-situ analysis of binding sites.Using this platform, 5-HT 1A Receptor agonists crocin I and crocin II with anti-insomnia and neuroprotective effects are successfully screened from saffron, and the action site is accurately depicted.